U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx Deal
Provided by
Dow Jones
By Mauro Orru
The U.K.'s Competition and Markets Authority is considering whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care technology could stifle competition in the country.
The CMA said Monday that it is seeking comments from any interested party until June 3 to inform its views on the deal, though it hasn't yet launched a formal investigation into the transaction.
Roche and LumiraDx struck an agreement in December. The companies didn't respond to requests for comment.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 20, 2024 02:38 ET (06:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now